和誉-B(02256)附属与阿斯利康达成战略合作开展同类首创口服PD-L1抑制剂ABSK043联合泰瑞沙®治疗非小细胞肺癌的临床研究

智通财经07-02

智通财经APP讯，和誉-B(02256)发布公告，本公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布，与阿斯利康(AstraZeneca，LSE/STO/NYSE: AZN)签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌(NSCLC)的临床研究。该联合研究是一项多中心、开放的I/II期临床试验，旨在评估和誉医药自主研发的同类首创(First-in-class)口服小分子PD-L1抑制剂 ABSK043(lumipodlin)联合阿斯利康第三代EGFR-TKI泰瑞沙^® (奥希替尼)，用于治疗EGFR突变合并PD-L1阳性的局部晚期或转移性NSCLC患者中的安全性和疗效。该研究的新药临床试验申请(IND)已于2026年5月20日获得国家药品监督管理局(NMPA)批准，本项II期研究由和誉医药主导，和誉医药和阿斯利康将共同承担该临床试验的相关职责。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2648220025?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-02 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648220025","market":"hk","top_or_hot":-1,"title":"和誉-B(02256)附属与阿斯利康达成战略合作开展同类首创口服PD-L1抑制剂ABSK043联合泰瑞沙®治疗非小细胞肺癌的临床研究","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02256\">和誉-B</a>(02256)发布公告，本公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布，与<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>(AstraZeneca，LSE/STO/NYSE: AZN)签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌(NSCLC)的临床研究。该联合研究是一项多中心、开放的I/II期临床试验，旨在评估和誉医药自主研发的同类首创(First-in-class)口服小分子PD-L1抑制剂 ABSK043(lumipodlin)联合阿斯利康第三代EGFR-TKI泰瑞沙<sup>®</sup> (奥希替尼)，用于治疗EGFR突变合并PD-L1阳性的局部晚期或转移性NSCLC患者中的安全性和疗效。该研究的新药临床试验申请(IND)已于2026年5月20日获得国家药品监督管理局(NMPA)批准，本项II期研究由和誉医药主导，和誉医药和阿斯利康将共同承担该临床试验的相关职责。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和誉-B(02256)附属与阿斯利康达成战略合作开展同类首创口服PD-L1抑制剂ABSK043联合泰瑞沙®治疗非小细胞肺癌的临床研究</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和誉-B(02256)附属与阿斯利康达成战略合作开展同类首创口服PD-L1抑制剂ABSK043联合泰瑞沙®治疗非小细胞肺癌的临床研究\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02256\">和誉-B</a>(02256)发布公告，本公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布，与<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>(AstraZeneca，LSE/STO/NYSE: AZN)签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌(NSCLC)的临床研究。该联合研究是一项多中心、开放的I/II期临床试验，旨在评估和誉医药自主研发的同类首创(First-in-class)口服小分子PD-L1抑制剂 ABSK043(lumipodlin)联合阿斯利康第三代EGFR-TKI泰瑞沙<sup>®</sup> (奥希替尼)，用于治疗EGFR突变合并PD-L1阳性的局部晚期或转移性NSCLC患者中的安全性和疗效。该研究的新药临床试验申请(IND)已于2026年5月20日获得国家药品监督管理局(NMPA)批准，本项II期研究由和誉医药主导，和誉医药和阿斯利康将共同承担该临床试验的相关职责。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1462072.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2468319806.SGD","symbol_name":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1462072.html","article_id":"2648220025","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648220025","pubTimestamp":1782950774,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，和誉-B 发布公告，本公司的附属公司上海和誉生物医药科技有限公司宣布，与阿斯利康签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌的临床研究。该联合研究是一项多中心、开放的I/II期临床试验，旨在评估和誉医药自主研发的同类首创口服小分子PD-L1抑制剂 ABSK043联合阿斯利康第三代EGFR-TKI泰瑞沙 ，用于治疗EGFR突变合并PD-L1阳性的局部晚期或转移性NSCLC患者中的安全性和疗效。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4007":"制药","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","02256":"和誉-B","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","PD":"PagerDuty, Inc.","AZNH":"ASTRAZENECA PLC ADRhedged","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4588":"碎股","BK4568":"美国抗疫概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","AZN":"阿斯利康","BK4023":"应用软件","BK1161":"生物科技","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD"},"translate_title":"Heyu-B (02256) affiliate reached a strategic cooperation with AstraZeneca to develop the first-in-class oral PD-L1 inhibitor ABSK043 combined with Teresa ® Clinical Study on Treatment of Non-small Cell Lung Cancer","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZNH":0.6,"AZN":1.5,"02256":1.5,"PD":1.5},"content_text":"智通财经APP讯，和誉-B(02256)发布公告，本公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布，与阿斯利康(AstraZeneca，LSE/STO/NYSE: AZN)签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌(NSCLC)的临床研究。该联合研究是一项多中心、开放的I/II期临床试验，旨在评估和誉医药自主研发的同类首创(First-in-class)口服小分子PD-L1抑制剂 ABSK043(lumipodlin)联合阿斯利康第三代EGFR-TKI泰瑞沙® (奥希替尼)，用于治疗EGFR突变合并PD-L1阳性的局部晚期或转移性NSCLC患者中的安全性和疗效。该研究的新药临床试验申请(IND)已于2026年5月20日获得国家药品监督管理局(NMPA)批准，本项II期研究由和誉医药主导，和誉医药和阿斯利康将共同承担该临床试验的相关职责。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648220025","isCrawlerRequest":true}